Dyspepsia is common within the general population and it imposes a significant burden on health-care resources.
Calculation of the economic implications of functional dyspepsia is constrained by the fact that it is only possible to make this diagnosis in a minority of individuals with the disorder, because many do not seek medical attention and investigation is not appropriate for all who do.
Studies which attempt to assess the effectiveness or cost-effectiveness of therapy may be further constrained by the fact that there is now good evidence that many patients with dyspepsia seek medical attention not so much because of the severity of symptoms, but because they fear that the symptoms signal the presence of some serious underlying disease.
In this situation, effective well-founded reassurance that no serious disease is present is an important outcome of medical intervention and one which should be included in an economic appraisal of dyspepsia management.
For obvious reasons, it is sensible to compare the cost-effectiveness of various clinical management strategies applicable in dyspepsia.
Decision-tree analyses are currently fashionable but suffer from the major defect that there is no theoretical basis from which patient satisfaction with treatment options can be assessed. (...)
Mots-clés Pascal : Analyse économique, Economie santé, Homme, Dyspepsie, Médicament, Analyse coût efficacité, Utilisation, Appareil digestif pathologie
Mots-clés Pascal anglais : Economic analysis, Health economy, Human, Dyspepsia, Drug, Cost efficiency analysis, Use, Digestive diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0108400
Code Inist : 002B30A01C. Création : 22/06/1998.